Gene-Product Auto-Targeting to Tumor Vessels
type: Grant
alternate name: 5R01CA120895-12
description: Project Summary Treatment options are limited and prognosis is poor for patients with recurrent or metastatic sarcoma. Both soft tissue sarcoma and osteosarcoma most frequently metastasize to the lungs and are often resistant to cytotoxic chemotherapy. Novel treatment options such as immune therapy are urgently needed for long-term control and elimination of metastatic disease. In that regard, both T cell (CAR-T and TILs) therapy and immune checkpoint blocking therapy have advanced to clinical applications in other types of tumors. In fact, wildtype IL12-armed T (CAR- or TIL) cells is more powerful in eliminating tumors than T cells alone in both preclinical tumor model or clinical trial because IL12 polarize T cells to the Th1 phenotype, boost effector T cells, downregulate angiogenesis, remodel the extracellular matrix, and alter levels of immune-suppressive cytokines. One urgent challenge for either CAR-T or wildtype IL12-armed T cell therapy is adverse effects. The CAR-T cells caus
amount: MonetaryAmount
  value: 339350
  currency: USD
funder: NIH — NIH
funder alt: US National Institutes of Health
recipient: UNIVERSITY OF TX MD ANDERSON CAN CTR
start date: 2007-08-01
end date: 2026-04-30
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://reporter.nih.gov/project-details/10373043
source organization: NIH RePORTER
publisher: AI Analytics
keywords: R01
keywords: NIH
keywords: 5

AI Analytics
type: Organization